Biosimilars offer a cost-effective solution to reduce healthcare costs while maintaining efficacy and safety. However, their uptake faces barriers such as patent litigation delaying market entry, and concerns about safety and efficacy. Strategies to increase biosimilars uptake include streamlining the approval process, educating healthcare professionals and patients, and fostering competition. The international experience attests to the cost-effectiveness of biosimilars, notably with significant savings in Europe and projected savings in the US.
IXON VPN Vulnerabilities Let Attackers Gain Access to Windows & Linux Systems
A security assessment by Shelltrail revealed three critical vulnerabilities in the IXON VPN client, allowing privilege escalation on Windows and Linux. Identified as CVE-2025-ZZZ-01, CVE-2025-ZZZ-02,
%20CISO%E2%80%99s%20Core%20Focus.webp?w=0&resize=0,0&ssl=1 "Identity and Access Management (IAM)")